Loading clinical trials...
Loading clinical trials...
An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
Conditions
Interventions
AAV-mediated REP1 gene replacement
Locations
2
United Kingdom
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Start Date
August 16, 2016
Primary Completion Date
July 23, 2021
Completion Date
July 23, 2021
Last Updated
August 5, 2021
NCT04483440
NCT02670980
NCT01603576
Lead Sponsor
University of Oxford
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions